LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2/STAT3 signaling

Cancer Gene Therapy, Published online: 24 January 2024; doi:10.1038/s41417-024-00726-2LOXL1-AS1 inhibits JAK2 ubiquitination and promotes cholangiocarcinoma progression through JAK2/STAT3 signaling

Source: Cancer Gene Therapy - January 24, 2024 Category: Cancer & Oncology Authors: Shaobo Yu Xin Gao Sidi Liu Xiangjun Sha Siyuan Zhang Xinmiao Zhang Dongsheng Sun Xingming Jiang Source Type: research